{"id":"NCT02819518","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)","officialTitle":"A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-27","primaryCompletion":"2021-06-15","completion":"2023-10-30","firstPosted":"2016-06-30","resultsPosted":"2022-07-05","lastUpdate":"2024-11-27"},"enrollment":882,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Triple Negative Breast Cancer (TNBC)"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"Nab-paclitaxel","otherNames":["ABRAXANE®"]},{"type":"DRUG","name":"Paclitaxel","otherNames":["TAXOL®"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["GEMZAR®"]},{"type":"DRUG","name":"Carboplatin","otherNames":["PARAPLATIN®"]},{"type":"DRUG","name":"Normale Saline Solution","otherNames":[]}],"arms":[{"label":"Part 1: Pembrolizumab + Nab-paclitaxel","type":"EXPERIMENTAL"},{"label":"Part 1: Pembrolizumab + Paclitaxel","type":"EXPERIMENTAL"},{"label":"Part 1: Pembrolizumab + Gemcitabine/Carboplatin","type":"EXPERIMENTAL"},{"label":"Part 2: Pembrolizumab + Chemotherapy","type":"EXPERIMENTAL"},{"label":"Part 2: Placebo + Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The study will consist of two parts.\n\nIn Part 1, the safety of pembrolizumab (MK-3475) in combination with one of three different chemotherapies will be assessed in the treatment of locally recurrent inoperable or metastatic triple negative breast cancer (TNBC), which has not been previously treated with chemotherapy.\n\nIn Part 2, the safety and efficacy of pembrolizumab plus background chemotherapy will be assessed compared to the safety and efficacy of placebo plus background chemotherapy in the treatment of locally recurrent inoperable or metastatic TNBC, which has not been previously treated with chemotherapy.\n\nThe primary hypotheses are that:\n\n1. the combination of pembrolizumab and chemotherapy prolongs Progression-Free Survival (PFS) compared to placebo and chemotherapy in:\n\n   * all participants,\n   * participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1 tumors, and\n   * participants with PD-L1 CPS ≥10 tumors, and\n2. the combination of pembrolizumab and chemotherapy prolongs Overall Survival (OS) compared to placebo and chemotherapy in:\n\n   * all participants,\n   * participants with PD-L1 CPS ≥1 tumors, and\n   * participants with PD-L1 CPS ≥10 tumors.","primaryOutcome":{"measure":"Part 1: Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants","timeFrame":"Up to approximately 39 months","effectByArm":[{"arm":"Part 1: Pembrolizumab + Nab-Paclitaxel","deltaMin":100,"sd":null},{"arm":"Part 1: Pembrolizumab + Paclitaxel","deltaMin":100,"sd":null},{"arm":"Part 1: Pembrolizumab + Gemcitabine/Carboplatin","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":20},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["39266535","35857659","33278935"],"seeAlso":["https://www.merckclinicaltrials.com","https://msd.trialsummaries.com/Study/StudyDetails?id=26179&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":13},"commonTop":["Anaemia","Nausea","Neutropenia","Alopecia","Fatigue"]}}